Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT

INCLUSION CRITERIA * Acute myelogenous leukemia (AML), beyond 2nd remission or relapsed/refractory disease, age 2 to 60 years * AML, in first or subsequent remission or relapsed/refractory disease, age 51 to 60 years of age * AML with multilineage dysplasia * Acute lymphoblastic leukemia (ALL), beyond 2nd remission or relapsed/refractory disease, age 2 to 60 years * ALL, age 51 - 60 years in first or subsequent remission or relapsed/refractory disease * Chronic myeloid leukemia (CML), beyond 2nd chronic phase or in blast crisis * Myelodysplastic syndrome (MDS), including World Health Organization (WHO)classifications of refractory anemia with excess blasts-1 (RAEB-1), RAEB-2 and therapy-related MDS * MDS with poor long-term survival including myeloid metaplasia and myelofibrosis * Myeloproliferative disorders * High-risk non-Hodgkin lymphoma (NHL) in 1st emission * Relapsed or refractory NHL * Hodgkin lymphoma (HL) beyond first remission * Males and females of any ethnic background, 2 to 60 years of age * Karnofsky Performance Status (KPS) ≥ 70% or Lansky performance status \> 70% for patients \< 16 years of age. * Related, matched-donor identified \[6/6 human leukocyte antigen (HLA)-A, B and DRB1\] * Willingness to take oral medications during the transplantation period * Ability to understand and the willingness to sign a written informed consent document EXCLUSION CRITERIA * Prior myeloablative allogeneic or autologous hematopoietic stem cell transplant (HSCT) * HIV infection * Pregnant * Lactating * Evidence of uncontrolled active infection * Serum creatinine \> 1.5 mg/dL or 24-hour creatinine clearance \< 50 mL/min * Direct bilirubin, Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2 x upper limit of normal (ULN) * Carbon monoxide diffusing capacity (DlCO) \< 60% predicted (adults) OR and in-room air oxygen saturation \< 92% (children) * Left ventricular ejection fraction \< 45% (adults) OR shortening fraction \< 26%(children) * Fasting cholesterol \> 300 mg/dL or Triglycerides \> 300 mg/dL while on lipid-lowering agents. * Receiving investigational drugs unless cleared by the Principal Investigator (PI). * Prior malignancies except basal cell carcinoma or treated carcinoma in-situ. * Cancer treated with curative intent ≤ 5 years (EXCEPTION BY PI DISCRETION) (Cancer treated with curative intent \> 5 years will be allowed).